India can be a real alternative to China in pharmaceuticals

Dependence on imported ingredients and quality assurance are being addressed

20240514 India

A Piramal Pharma lab in Mumbai: Indian companies are investing aggressively to expand their capabilities and offerings into more complex and high-value product lines. © Reuters

Gopal Nadadur is based in New Delhi as vice president for South Asia at The Asia Group, a strategic advisory firm. Sam Ide is based in Washington as the firm's vice president for China.

The COVID pandemic was a wake-up call for many governments about the public health and national security risks of overreliance on a narrow set of partner countries for pharmaceuticals, medical technologies and other health care products.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.